FIL Ltd lessened its holdings in iKang Healthcare Group Inc (NASDAQ:KANG) by 19.5% in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 747,783 shares of the medical research company’s stock after selling 181,684 shares during the period. FIL Ltd owned about 1.08% of iKang Healthcare Group worth $14,918,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in KANG. NINE MASTS CAPITAL Ltd acquired a new position in iKang Healthcare Group during the 1st quarter worth $8,829,000. Maso Capital Partners Ltd boosted its stake in iKang Healthcare Group by 15.1% in the 1st quarter. Maso Capital Partners Ltd now owns 1,731,257 shares of the medical research company’s stock worth $34,539,000 after purchasing an additional 227,195 shares during the period. OMERS ADMINISTRATION Corp boosted its stake in iKang Healthcare Group by 905.3% in the 1st quarter. OMERS ADMINISTRATION Corp now owns 132,700 shares of the medical research company’s stock worth $2,647,000 after purchasing an additional 119,500 shares during the period. JPMorgan Chase & Co. acquired a new position in iKang Healthcare Group in the 1st quarter worth $147,000. Finally, BlackRock Inc. boosted its stake in iKang Healthcare Group by 10.3% in the 1st quarter. BlackRock Inc. now owns 883,929 shares of the medical research company’s stock worth $17,635,000 after purchasing an additional 82,195 shares during the period. 38.95% of the stock is owned by hedge funds and other institutional investors.
A number of research firms have recently commented on KANG. ValuEngine upgraded shares of iKang Healthcare Group from a “hold” rating to a “buy” rating in a research note on Saturday, June 2nd. BidaskClub cut shares of iKang Healthcare Group from a “buy” rating to a “hold” rating in a report on Wednesday, May 16th.
iKang Healthcare Group (NASDAQ:KANG) last released its quarterly earnings data on Thursday, March 22nd. The medical research company reported $0.40 earnings per share (EPS) for the quarter. The firm had revenue of $206.39 million during the quarter. iKang Healthcare Group had a return on equity of 4.97% and a net margin of 3.16%.
iKang Healthcare Group Profile
iKang Healthcare Group, Inc, together with its subsidiaries, provides preventive healthcare solutions in the People's Republic of China. The company operates in two segments, Medical Examinations and Other Medical Services, and Dental Services. It offers a range of medical examinations, including internal, gynecology, ophthalmology, ENT, dental, lab tests, electrocardiogram, ultrasound, and X-ray examination items.
Receive News & Ratings for iKang Healthcare Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iKang Healthcare Group and related companies with MarketBeat.com's FREE daily email newsletter.